# Ranolazine Implantable Cardioverter-Defibrillator Trial

> **NCT01215253** · PHASE3 · COMPLETED · sponsor: **University of Rochester** · enrollment: 1012 (actual)

## Conditions studied

- Ischemic Cardiomyopathy
- Nonischemic Cardiomyopathy
- Heart Failure

## Interventions

- **DRUG:** Ranolazine

## Key facts

- **NCT ID:** NCT01215253
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2017-02-28
- **Final completion:** 2017-02-28
- **Target enrollment:** 1012 (ACTUAL)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215253, "Ranolazine Implantable Cardioverter-Defibrillator Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01215253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*